Home » Stocks » MBIO

Mustang Bio, Inc. (MBIO)

Stock Price: $2.70 USD -0.17 (-5.92%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $2.78 +0.08 (2.96%) May 13, 5:58 PM
Market Cap 235.93M
Revenue (ttm) -50,000
Net Income (ttm) -60.02M
Shares Out 52.59M
EPS (ttm) -1.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $2.70
Previous Close $2.87
Change ($) -0.17
Change (%) -5.92%
Day's Open 2.90
Day's Range 2.68 - 2.96
Day's Volume 2,468,643
52-Week Range 2.42 - 5.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Fred Hutchinson Cancer Research Center to present updated interim data from ongoing MB-106 Phase 1/2 clinical trial Fred Hutchinson Cancer Research Center to present updated interim data from ongoing MB...

1 day ago - GlobeNewsWire

The Phase 1/2 multicenter study to assess the safety, tolerability and efficacy of MB-106 in patients with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia is ex...

3 days ago - GlobeNewsWire

NEW YORK, March 24, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gen...

1 month ago - GlobeNewsWire

WORCESTER, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

2 months ago - GlobeNewsWire

Many penny stocks are destined to fail, but these seven penny stocks may succeed. Wall Street has buy recommedations on them.

Other stocks mentioned: ALNA, ALRN, MCHX, MDWD, OBSV, RWLK
3 months ago - InvestorPlace

Mustang Bio (NASDAQ: MBIO) shares are trading higher after the company announced the FDA has lifted the clinical hold for its pivotal phase 2 MB-107 clinical trial. The company plans to enroll the first...

Other stocks mentioned: PHAT, BNGO, IMVT
3 months ago - Benzinga

FDA removes clinical hold for pivotal Phase 2 MB-107 clinical trial

3 months ago - GlobeNewsWire

Penny stocks are cheap for a reason, as there are obvious flaws. However, with those flows comes opportunity.

Other stocks mentioned: CAIXY, CLVS, DHT, OPK, RNWK, RYCEY
3 months ago - InvestorPlace

WORCESTER, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

4 months ago - GlobeNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...

Other stocks mentioned: FL, GME, NTAP, ARVN, BCAB, COUP, EOSE ...
4 months ago - Benzinga

Data presented at the 62 nd American Society of Hematology (ASH) Annual Meeting show extremely favorable safety profile and clinical activity

5 months ago - GlobeNewsWire

Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.

5 months ago - Zacks Investment Research

Call to be held Wednesday, December 9, 2020, at 1:00 p.m. EST Call to be held Wednesday, December 9, 2020, at 1:00 p.m. EST

5 months ago - GlobeNewsWire

WORCESTER, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

5 months ago - GlobeNewsWire

WORCESTER, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

6 months ago - GlobeNewsWire

WORCESTER, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell ...

6 months ago - GlobeNewsWire

Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.

Other stocks mentioned: ABBV, AMGN, BLUE, BMY, REGN, VRTX
6 months ago - InvestorPlace

Data presented by City of Hope at 27th Annual Prostate Cancer Foundation Scientific Retreat Data presented by City of Hope at 27th Annual Prostate Cancer Foundation Scientific Retreat

6 months ago - GlobeNewsWire

WORCESTER, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell ...

7 months ago - GlobeNewsWire

Mustang to leverage LentiBOOST™ for the development of MB-207 lentiviral gene therapy Mustang to leverage LentiBOOST™ for the development of MB-207 lentiviral gene therapy

7 months ago - GlobeNewsWire

WORCESTER, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell ...

7 months ago - GlobeNewsWire

WORCESTER, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in ce...

7 months ago - GlobeNewsWire

Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

WORCESTER, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cel...

8 months ago - GlobeNewsWire

Mustang Bio: Slow, Steady Progress Towards Multiple Gene And CAR-T Therapy Goals

8 months ago - Seeking Alpha

Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research

WORCESTER, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cel...

8 months ago - GlobeNewsWire

WORCESTER, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cel...

9 months ago - GlobeNewsWire

Mustang Bio (MBIO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

Mustang Bio, Inc. (NASDAQ: MBIO) shares are trading lower after the company announced a common stock offering of 10.769 million shares at $3.25 per share.

11 months ago - Benzinga

Mustang Bio (MBIO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

11 months ago - Zacks Investment Research

WORCESTER, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cel...

11 months ago - GlobeNewsWire

Mustang (MBIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

NEW YORK, April 20, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and g...

1 year ago - GlobeNewsWire

The subject achieved a complete response The subject achieved a complete response

1 year ago - GlobeNewsWire

NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and ge...

1 year ago - GlobeNewsWire

Mustang Bio, Inc. (MBIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

The American Society of Hematology's 61st annual meeting is underway in Orlando, Florida.

Other stocks mentioned: DTIL, FTSV, RHHBY, TGTX
1 year ago - Benzinga

As investors consider the current market conditions today, many should be prepared for what is coming and how looking beyond the benchmark through customized ETF strategies may help diversify risks ahead.

Other stocks mentioned: DIAL, RECS, REVS
1 year ago - ETF Trends

First dose occurred in trial currently underway at the University of Alabama at Birmingham First dose occurred in trial currently underway at the University of Alabama at Birmingham

1 year ago - GlobeNewsWire

NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and g...

1 year ago - GlobeNewsWire

NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and g...

1 year ago - GlobeNewsWire

NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and g...

1 year ago - GlobeNewsWire

RMAT designation follows positive Phase 1/2 clinical data published in the New England Journal of Medicine

1 year ago - GlobeNewsWire

Mustang Bio presented positive data from a phase 1/2 study using MB-107 to treat patients with a rare disease known as X-linked severe combined immunodeficiency.

2 years ago - Seeking Alpha

Mustang Bio, Inc. soared last Thursday after the very successful results of its gene therapy.

Other stocks mentioned: FBIO
2 years ago - Seeking Alpha

A new gene therapy could be a functional cure for "bubble boy" disease.

2 years ago - The Motley Fool

Mustang Bio Inc. shares more than tripled on Thursday after the company announced a breakthrough that cured eight infants dealing with the “Bubble Boy” immune disorder.

2 years ago - 24/7 Wall Street

Shares of Mustang Bio Inc (NASDAQ: MBIO) are skyrocketing to their highest level in about a year Thursday morning.

2 years ago - Benzinga

Shares of Mustang Bio Inc. blasted off to a near 4-fold gain (up 257%) in premarket trade Thursday.

2 years ago - Market Watch

About MBIO

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare g... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
MBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Mustang Bio stock is "Strong Buy." The 12-month stock price forecast is 10.25, which is an increase of 279.63% from the latest price.

Price Target
$10.25
(279.63% upside)
Analyst Consensus: Strong Buy